Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.
- Registry ID
- EUCTR2007-004322-24
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Lundbeck Inc
- Start date
- 2008-03-17
- Completion date
- 2010-04-23
- Last update
- 2026-08-16
Conditions
Summary
1. To determine the efficacy of clobazam (CLB) in the reduction of drop seizures at three dose levels when compared to baseline during 12 weeks maintenance dosing in a placebo controlled trial in patients with Lennox-Gastaut Syndrome (LGS). 2. To determine the safety of CLB when administered for up to 18 weeks at three different dose levels in patients with LGS.
Locations
- , , Lithuania
- , , Bulgarian Drug Agency
Related clinical trials
View on source registry